K-Ras G12C-IN-1 is primarily used in research and development for targeting specific mutations in cancer therapy. It is designed to inhibit the K-Ras G12C mutant protein, which is commonly found in various cancers such as lung, colorectal, and pancreatic cancers. By selectively binding to the mutant protein, it helps to block the signaling pathways that promote tumor growth and survival. This makes it a promising candidate for precision medicine, offering potential therapeutic benefits for patients with K-Ras G12C-driven cancers. Its application is mainly focused on preclinical studies to evaluate efficacy, safety, and mechanisms of action, contributing to the development of targeted cancer treatments.